Minimal Residual Disease Assessed by Multiparameter
Impact on Outcome in the Medical Research Council My

Journal of Clinical Oncology

31, 2540-2547

DOI: 10.1200/jco.2012.46.2119

Citation Report

#	Article	IF	Citations
1	Evolving Strategies in the Initial Treatment of Multiple Myeloma. Seminars in Oncology, 2013, 40, 592-601.	2.2	5
2	Role of Consolidation Therapy in Transplant Eligible Multiple Myeloma Patients. Seminars in Oncology, 2013, 40, 610-617.	2.2	10
4	Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematology American Society of Hematology Education Program, 2013, 2013, 496-503.	2.5	26
5	Minimal Residual Disease in Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 2523-2526.	1.6	44
6	Transplants for the elderly in myeloma. Blood, 2013, 122, 1332-1334.	1.4	7
7	B-cell malignancies: capture-sequencing strategies for identification of gene rearrangements and translocations into immunoglobulin gene loci. Blood and Lymphatic Cancer: Targets and Therapy, 2014, , 107.	2.7	0
8	Multiple myeloma: optimal management and long-term disease control. Blood and Lymphatic Cancer: Targets and Therapy, 2014, , 121.	2.7	0
9	Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area. Journal of Clinical Oncology, 2014, 32, 2125-2132.	1.6	22
10	Utility of Nine-Color, 11-Parameter Flow Cytometry for Detection of Plasma Cell Neoplasms. American Journal of Clinical Pathology, 2014, 142, 398-410.	0.7	7
11	Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDAâ€NCI roundtable symposium. American Journal of Hematology, 2014, 89, 1159-1160.	4.1	52
12	Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. Ca-A Cancer Journal for Clinicians, 2014, 64, 422-444.	329.8	85
13	All transplantation-eligible patients with myeloma should receive ASCT in first response. Hematology American Society of Hematology Education Program, 2014, 2014, 250-254.	2.5	13
14	Implications of Heterogeneity in Multiple Myeloma. BioMed Research International, 2014, 2014, 1-12.	1.9	43
15	Multiple myeloma: a model for scientific and clinical progress. Hematology American Society of Hematology Education Program, 2014, 2014, 1-7.	2.5	17
16	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. Hematology American Society of Hematology Education Program, 2014, 2014, 255-261.	2.5	25
17	Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques. Current Hematologic Malignancy Reports, 2014, 9, 368-378.	2.3	18
18	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99, 232-242.	3.5	185
19	Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 1113-1129.	2.2	4

#	Article	IF	Citations
20	The Road to Treating Smoldering Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S59-S64.	0.4	2
21	United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma. International Journal of Laboratory Hematology, 2014, 36, 665-675.	1.3	1
22	Development of beadâ€based suspension array technology for the diagnosis of thalassemia. American Journal of Hematology, 2014, 89, 1158-1159.	4.1	5
23	Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma. Advances in Hematology, 2014, 2014, 1-12.	1.0	11
24	Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leukemia Research, 2014, 38, 371-376.	0.8	76
26	Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. , 2014, , n/a-n/a.		7
27	What We Mean When We Talk About MRD in Myeloma. A Review of Current Methods. Part 1 of a Two-Part Series. Current Hematologic Malignancy Reports, 2014, 9, 379-388.	2.3	3
28	Initial treatment of transplant-ineligible patients in multiple myeloma. Expert Review of Hematology, 2014, 7, 67-77.	2.2	8
29	The current status of minimal residual disease assessment in myeloma. Leukemia, 2014, 28, 239-240.	7.2	19
30	Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 356-369.	0.4	7
31	Minimal Residual Disease: What Are the Minimum Requirements?. Journal of Clinical Oncology, 2014, 32, 475-476.	1.6	21
32	High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI) Tj ETQq1 1 0.784314 rgBT /Overlo 15, 874-885.	10.7	139
33	European Perspective on Multiple Myeloma Treatment Strategies in 2014. Oncologist, 2014, 19, 829-844.	3.7	90
34	Recent advancements of flow cytometry: new applications in hematology and oncology. Expert Review of Molecular Diagnostics, 2014, 14, 67-81.	3.1	38
35	Complete response after autologous stem cell transplant in multiple myeloma. Cancer Medicine, 2014, 3, 939-946.	2.8	23
36	Diagnosis and Risk Stratification in Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 791-813.	2.2	19
37	Maintenance Therapy for Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 839-859.	2.2	14
38	Can we safely target the WNT pathway?. Nature Reviews Drug Discovery, 2014, 13, 513-532.	46.4	840

#	Article	IF	Citations
39	Diagnostic and prognostic significance of CD200 expression and its stability in plasma cell myeloma. Journal of Clinical Pathology, 2014, 67, 792-796.	2.0	19
40	Response evaluation and monitoring of multiple myeloma. Expert Review of Hematology, 2014, 7, 33-42.	2.2	8
41	Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du MyÃ©lome. Journal of Clinical Oncology, 2014, 32, 2712-2717.	1.6	243
42	Reply to M. Roschewski et al. Journal of Clinical Oncology, 2014, 32, 476-477.	1.6	0
43	Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 154-163.	2.0	36
44	Reprint of: Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, S8-S17.	2.0	3
45	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood, 2014, 123, 3073-3079.	1.4	380
46	The future of autologous stem cell transplantation in myeloma. Blood, 2014, 124, 328-333.	1.4	40
47	Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood, 2014, 124, 1296-1299.	1.4	48
48	The evolving field of post-transplant therapy in multiple myeloma. Clinical Investigation, 2014, 4, 825-838.	0.0	0
49	Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. Haematologica, 2014, 99, 1611-1617.	3.5	29
50	Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5â€year followâ€up. British Journal of Haematology, 2015, 171, 344-354.	2.5	26
51	Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood, 2015, 125, 1932-1935.	1.4	163
52	Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma. Journal of Translational Medicine, 2015, 13, 197.	4.4	6
53	Detection of minimal residual disease in <scp>B</scp> lymphoblastic leukemia using vi<scp>SNE</scp>. Cytometry Part B - Clinical Cytometry, 2015, 88, 294-304.	1.5	39
54	Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. British Journal of Haematology, 2015, 171, 453-462.	2.5	27
55	Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates. International Journal of Laboratory Hematology, 2015, 37, 797-808.	1.3	11
56	Consolidation and maintenance inde novofirst-line multiple myeloma with modern agents. International Journal of Hematologic Oncology, 2015, 4, 9-22.	1.6	1

#	Article	IF	Citations
57	Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e493-e503.	3.8	11
58	Deep Response in Multiple Myeloma: A Critical Review. BioMed Research International, 2015, 2015, 1-7.	1.9	32
59	The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. Haematologica, 2015, 100, e53-e55.	3.5	41
60	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2015, 1, 746.	7.1	266
61	Dilemmas in Treating Smoldering Multiple Myeloma. Journal of Clinical Oncology, 2015, 33, 115-123.	1.6	19
62	Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen. Journal of Medicinal Chemistry, 2015, 58, 1717-1735.	6.4	65
63	Pretransplant Induction Regimens for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 200-201.	2.0	1
64	Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nature Reviews Clinical Oncology, 2015, 12, 286-295.	27.6	97
65	Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. , 2015, 88, 101-109.		9
66	Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2015, 50, 511-516.	2.4	6
67	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1155-1166.	2.0	104
68	Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Reviews, 2015, 29, 387-403.	5.7	48
69	Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leukemia and Lymphoma, 2015, 56, 1416-1424.	1.3	23
71	Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?. Bone Marrow Transplantation, 2015, 50, 1024-1029.	2.4	31
72	Application of biomarkers in oncology clinical trials. Clinical Investigation, 2015, 5, 61-74.	0.0	1
73	New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood, 2015, 125, 3059-3068.	1.4	256
74	Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?. Clinical Cancer Research, 2015, 21, 2001-2008.	7.0	41
75	The Role of Pre-Transplant Induction Regimens and Autologous Stem Cell Transplantation in the Era of Novel Targeted Agents. Drugs, 2015, 75, 367-375.	10.9	5

#	Article	IF	Citations
76	Critical methodological factors in diagnosing minimal residual disease in hematological malignancies using quantitative PCR. Expert Review of Molecular Diagnostics, 2015, 15, 581-584.	3.1	2
77	Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. Blood Cancer Journal, 2015, 5, e285-e285.	6.2	82
78	CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Human Vaccines and Immunotherapeutics, 2015, 11, 1606-1611.	3.3	26
79	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma. Journal of Molecular Diagnostics, 2015, 17, 652-660.	2.8	115
80	The Use of Immunoglobulin Gene Rearrangement Polymerase Chain Reaction Assays for Detection of B-Cell Clonality for Plasma Cell Neoplasms Using Novel PCR Primers. Journal of Molecular Biomarkers & Diagnosis, 2016, 07, .	0.4	0
81	Multiple myeloma, immunotherapy and minimal residual disease. Neoplasma, 2016, 63, 651-658.	1.6	1
82	Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e425-e430.	3.8	14
83	Towards Stratified Medicine in Plasma Cell Myeloma. International Journal of Molecular Sciences, 2016, 17, 1760.	4.1	9
84	Chimeric Antigen Receptor (<scp>CAR</scp>) therapy for multiple myeloma. British Journal of Haematology, 2016, 172, 685-698.	2.5	53
85	A <scp>CD</scp>138â€independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma. British Journal of Haematology, 2016, 173, 70-81.	2.5	20
86	The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in China. Kidney Diseases (Basel, Switzerland), 2016, 1, 235-240.	2.5	10
87	Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer Journal, 2016, 6, e506-e506.	6.2	68
88	Utility of flow cytometry studies in the management of patients with multiple myeloma. Current Opinion in Oncology, 2016, 28, 511-517.	2.4	20
89	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 379-386.	0.4	17
90	Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. Haematologica, 2016, 101, e69-e71.	3.5	41
91	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood, 2016, 127, 681-695.	1.4	179
92	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood, 2016, 127, 3165-3174.	1.4	129
93	Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplantation, 2016, 51, 1565-1568.	2.4	160

#	Article	IF	Citations
94	Advances in understanding prognosis in myeloma. British Journal of Haematology, 2016, 175, 367-380.	2.5	27
95	Multiple Myeloma Minimal Residual Disease. Cancer Treatment and Research, 2016, 169, 103-122.	0.5	19
96	Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response. Leukemia and Lymphoma, 2016, 57, 1786-1792.	1.3	13
97	FLOCK cluster analysis of plasma cell flow cytometry data predicts bone marrow involvement by plasma cell neoplasia. Leukemia Research, 2016, 48, 40-45.	0.8	8
98	Immunotherapies targeting CD38 in Multiple Myeloma. OncoImmunology, 2016, 5, e1217374.	4.6	33
99	Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents. Cytometry Part B - Clinical Cytometry, 2016, 90, 81-90.	1.5	45
100	Flow cytometry characterization in central nervous system and pleural effusion multiple myeloma infiltration: an Italian national cancer institute experience. British Journal of Haematology, 2016, 172, 980-982.	2.5	11
101	Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry Part B - Clinical Cytometry, 2016, 90, 31-39.	1.5	144
102	Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for <scp>MRD</scp> detection in multiple myeloma. Cytometry Part B - Clinical Cytometry, 2016, 90, 61-72.	1.5	177
103	Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service. Cytometry Part B - Clinical Cytometry, 2016, 90, 54-60.	1.5	20
104	Assessment of minimal residual disease in myeloma and the need for a consensus approach. Cytometry Part B - Clinical Cytometry, 2016, 90, 21-25.	1.5	35
105	Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. Cytometry Part B - Clinical Cytometry, 2016, 90, 14-20.	1.5	35
106	Myeloma minimal residual disease testing in the United States: Evidence of improved standardization. American Journal of Hematology, 2016, 91, E502-E503.	4.1	18
107	Management of multiple myeloma in resource-constrained settings. Seminars in Oncology, 2016, 43, 690-694.	2.2	4
108	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
109	Multiple myeloma: disease response assessment. Expert Review of Hematology, 2016, 9, 831-837.	2.2	8
110	Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma. Seminars in Oncology, 2016, 43, 709-711.	2.2	5
111	Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2383-2396.	2.5	6

#	Article	IF	Citations
112	The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. BMC Hematology, 2016, 16, 14.	2.6	7
113	Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study. Journal of Experimental and Clinical Cancer Research, 2016, 35, 49.	8.6	4
114	Management of high-risk Myeloma: an evidence-based review of treatment strategies. Expert Review of Hematology, 2016, 9, 753-765.	2.2	4
115	Oral ixazomib maintenance therapy in multiple myeloma. Expert Review of Anticancer Therapy, 2016, 16, 21-32.	2.4	6
116	Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. Current Hematologic Malignancy Reports, 2016, 11, 118-126.	2.3	11
117	Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma. Cytometry Part B - Clinical Cytometry, 2016, 90, 73-80.	1.5	24
118	Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma. Cytometry Part B - Clinical Cytometry, 2016, 90, 40-46.	1.5	22
119	Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Current Hematologic Malignancy Reports, 2016, 11, 127-136.	2.3	20
120	Is it possible to cure myeloma without allogeneic transplantation?. Transfusion and Apheresis Science, 2016, 54, 63-70.	1.0	10
121	Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e27-e37.	0.4	1
122	MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients. Bone Marrow Transplantation, 2016, 51, 913-914.	2.4	19
123	Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration. Clinical Chemistry, 2016, 62, 243-251.	3.2	57
124	Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2016, 51, 2-12.	2.4	16
125	Plasma Cell Neoplasms. , 2016, , .		37
126	Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry Part B - Clinical Cytometry, 2016, 90, 47-53.	1.5	118
127	Potential therapeutic targets in plasma cell disorders: A flow cytometry study. Cytometry Part B - Clinical Cytometry, 2017, 92, 145-152.	1.5	13
128	Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 165-172.	0.4	17
129	Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia, 2017, 31, 2094-2103.	7.2	486

#	Article	IF	Citations
130	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. Biology of Blood and Marrow Transplantation, 2017, 23, 598-605.	2.0	47
131	Maintenance therapy in multiple myeloma. Therapeutic Advances in Hematology, 2017, 8, 71-79.	2.5	7
132	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clinical Cancer Research, 2017, 23, 3980-3993.	7.0	71
133	Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. Bone Marrow Transplantation, 2017, 52, 1194-1198.	2.4	27
134	Time to publish: challenging the performance of cooperative group lymphoma trials. Lancet Haematology,the, 2017, 4, e8-e10.	4.6	2
135	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica, 2017, 102, e313-e316.	3.5	26
136	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 230-269.	4.9	166
137	Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. British Journal of Haematology, 2017, 179, 198-218.	2.5	47
138	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood, 2017, 130, 440-452.	1.4	66
139	Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer Journal, 2017, 7, e545-e545.	6.2	40
140	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. New England Journal of Medicine, 2017, 376, 1311-1320.	27.0	924
141	Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma. Bone Marrow Transplantation, 2017, 52, 839-845.	2.4	4
142	Phase <scp>II</scp> study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: <scp>DSMM XI</scp> trial. British Journal of Haematology, 2017, 179, 586-597.	2.5	30
143	Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer Journal, 2017, 7, e617-e617.	6.2	45
144	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematology,the, 2017, 4, e431-e442.	4.6	132
145	Standardisation of minimal residual disease in multiple myeloma. European Journal of Cancer Care, 2017, 26, e12732.	1.5	9
146	Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry. Clinics in Laboratory Medicine, 2017, 37, 821-853.	1.4	20
147	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert Opinion on Pharmacotherapy, 2017, 18, 1975-1985.	1.8	10

#	Article	IF	Citations
148	Targeted therapy and maintenance in myeloma. British Medical Bulletin, 2017, 122, 163-178.	6.9	0
149	Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma. Leukemia and Lymphoma, 2017, 58, 1234-1237.	1.3	13
150	Diagnosis of chronic lymphoproliferative disorders by flow cytometry using fourâ€color combinations for immunophenotyping: A proposal of the brazilian group of flow cytometry (GBCFLUX). Cytometry Part B - Clinical Cytometry, 2017, 92, 398-410.	1.5	6
151	Association between complete response and outcomes in transplantâ€eligible myeloma patients in the era of novel agents. European Journal of Haematology, 2017, 98, 269-279.	2.2	28
152	Minimal Residual Disease as a Potential Surrogate End Pointâ€"Lingering Questions. JAMA Oncology, 2017, 3, 18.	7.1	15
153	Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma. JAMA Oncology, 2017, 3, 28.	7.1	405
154	High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Blood Cancer Journal, 2017, 7, e590-e590.	6.2	68
155	Autologous hematopoietic cell transplants for plasma cell myeloma: One, two, or none?. , 0, , 445-457.		0
156	Maintenance therapy in plasma cell myeloma after autologous transplant. , 0, , 458-467.		0
157	Is molecular remission the goal of multiple myeloma therapy?. Hematology American Society of Hematology Education Program, 2017, 2017, 205-211.	2.5	17
158	MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Advances, 2017, 1, 728-732.	5.2	84
159	Should minimal residual disease negativity not be the end point of myeloma therapy?. Blood Advances, 2017, 1, 522-525.	5.2	5
160	Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation. Journal of Clinical Medicine, 2017, 6, 91.	2.4	29
161	The Evolution of Prognostic Factors in Multiple Myeloma. Advances in Hematology, 2017, 2017, 1-11.	1.0	49
162	VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma. OncoTargets and Therapy, 2017, Volume 10, 217-226.	2.0	5
163	Should minimal residual disease negativity be the end point of myeloma therapy?. Blood Advances, 2017, 1, 517-521.	5.2	10
164	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. Journal of Clinical Oncology, 2017, 35, 3279-3289.	1.6	535
165	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. Journal of Clinical Oncology, 2017, 35, 2900-2910.	1.6	248

#	Article	IF	Citations
166	Myeloma in Elderly Patients: When Less Is More and More Is More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 575-585.	3.8	16
167	Plasma Cell Myeloma and Related Disorders. , 0, , 128-139.		0
168	The multiple myelomas â€" current concepts in cytogenetic classification and therapy. Nature Reviews Clinical Oncology, 2018, 15, 409-421.	27.6	203
169	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 889-894.	4.1	14
170	Minimal Residual Disease in Multiple Myeloma. Hematologic Malignancies, 2018, , 97-109.	0.2	2
171	Treatment of Elderly Patients with Multiple Myeloma. Hematologic Malignancies, 2018, , 61-71.	0.2	1
172	Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. Modern Pathology, 2018, 31, 881-889.	5.5	8
173	Molecular detection of minimal residual disease in multiple myeloma. British Journal of Haematology, 2018, 181, 11-26.	2.5	39
174	Analysis of longâ€term survival in multiple myeloma after firstâ€line autologous stem cell transplantation: impact of clinical risk factors and sustained response. Cancer Medicine, 2018, 7, 307-316.	2.8	42
175	Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies. Cytometry Part B - Clinical Cytometry, 2018, 94, 509-519.	1.5	14
176	Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders. Methods in Molecular Biology, 2018, 1768, 229-256.	0.9	24
177	Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?. Seminars in Hematology, 2018, 55, 4-12.	3.4	16
178	Development of an unbiased, semiâ€automated approach for classifying plasma cell immunophenotype following multicolor flow cytometry of bone marrow aspirates. Cytometry Part B - Clinical Cytometry, 2018, 94, 758-766.	1.5	3
179	Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. Leukemia, 2018, 32, 376-382.	7.2	16
180	Minimal residual disease in multiple myeloma: Benefits of flow cytometry. International Journal of Laboratory Hematology, 2018, 40, 12-20.	1.3	8
182	Minimal residual disease analysis in myeloma â€" when, why and where. Leukemia and Lymphoma, 2018, 59, 1772-1784.	1.3	19
183	Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry. Cytometry Part B - Clinical Cytometry, 2018, 94, 484-492.	1.5	9
184	Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia, 2018, 32, 971-978.	7.2	38

#	Article	IF	Citations
185	BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 2018, 24, 641-648.	2.0	19
186	Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma. Cytometry Part B - Clinical Cytometry, 2018, 94, 493-499.	1.5	13
187	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 155-161.	2.4	8
188	Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity. Advances in Experimental Medicine and Biology, 2018, 1100, 141-159.	1.6	9
189	New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies. Journal of Clinical Medicine, 2018, 7, 288.	2.4	24
190	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood, 2018, 132, 2456-2464.	1.4	301
191	Prognostic factors for multiple myeloma in the era of novel therapies. Expert Review of Hematology, 2018, 11, 863-879.	2.2	28
192	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 2018, 103, 1772-1784.	3.5	86
193	Liquid Biopsy in Multiple Myeloma. , 0, , .		4
194	Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA. Journal of Molecular Diagnostics, 2018, 20, 859-870.	2.8	45
195	Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells International, 2018, 2018, 1-16.	2.5	593
196	Longitudinal Flow Cytometry Identified â€œMinimal Residual Diseaseâ€•(MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 2568-2574.	2.0	37
197	Remission maintenance treatment options in chronic lymphocytic leukemia. Cancer Treatment Reviews, 2018, 70, 56-66.	7.7	2
198	ELDA qASO-PCR for High Sensitivity Detection of Tumor Cells in Bone Marrow and Peripheral Blood. Methods in Molecular Biology, 2018, 1792, 1-14.	0.9	3
199	Novel biomarkers in multiple myeloma. Translational Research, 2018, 201, 49-59.	5.0	31
200	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leukemia and Lymphoma, 2019, 60, 442-452.	1.3	15
201	Methods and role of minimal residual disease after stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 681-690.	2.4	7
202	Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone. European Journal of Haematology, 2019, 103, 385-392.	2.2	1

#	Article	IF	Citations
203	Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry. Current Protocols in Cytometry, 2019, 90, e63.	3.7	13
204	Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. British Journal of Haematology, 2019, 186, 807-819.	2.5	14
205	Flow Cytometric Immunophenotypic Analysis in the Diagnosis and Prognostication of Plasma Cell Neoplasms. Cytometry Part B - Clinical Cytometry, 2019, 96, 338-350.	1.5	15
206	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematology,the, 2019, 6, e616-e629.	4.6	42
207	Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives. Frontiers in Oncology, 2019, 9, 699.	2.8	43
208	Quantitative phase imaging of cells in a flow cytometry arrangement utilizing Michelson interferometerâ€based offâ€axis digital holographic microscopy. Journal of Biophotonics, 2019, 12, e201900085.	2.3	39
209	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet, The, 2019, 394, 29-38.	13.7	665
210	VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era. International Journal of Hematology, 2019, 110, 322-330.	1.6	20
211	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2039-2050.	2.4	9
212	High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2027-2038.	2.4	20
213	Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma. Scientific Reports, 2019, 9, 2922.	3.3	12
214	Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells. Cancers, 2019, 11, 439.	3.7	25
215	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology, 2019, 94, 751-756.	4.1	15
216	Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis. Annals of Hematology, 2019, 98, 1185-1195.	1.8	23
217	Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e213-e220.	0.4	9
218	Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies. Methods in Molecular Biology, 2019, 1956, 157-197.	0.9	8
219	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. HemaSphere, 2019, 3, e300.	2.7	20
220	Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood, 2019, 134, 2218-2222.	1.4	66

#	Article	IF	Citations
221	Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. Cancers, 2019, 11, 2015.	3.7	26
222	Minimal residual disease (mrd) in multiple myeloma: prognostic and therapeutic implications (including imaging). HemaSphere, 2019, 3, 124-126.	2.7	0
223	Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood, 2019, 133, 660-675.	1.4	136
224	Minimal residual disease by flow cytometry and allelicâ€specific oligonucleotide realâ€time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. Cancer, 2019, 125, 750-760.	4.1	31
225	Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international interâ€laboratory study: Is it ready for primetime use?. Cytometry Part B - Clinical Cytometry, 2019, 96, 201-208.	1.5	15
226	BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma. Cytometry Part B - Clinical Cytometry, 2019, 96, 209-214.	1.5	8
227	The role of surface molecule CD229 in Multiple Myeloma. Clinical Immunology, 2019, 204, 69-73.	3.2	9
228	Serological normalisation as a surrogate marker for minimal residual disease negativity in multiple myeloma. British Journal of Haematology, 2019, 185, 775-778.	2.5	2
229	Minimal residual disease and logâ€reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma. Cytometry Part B - Clinical Cytometry, 2019, 96, 195-200.	1.5	11
230	High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, 239-247.	2.0	27
231	Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia, 2020, 34, 578-588.	7.2	20
232	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e30-e37.	0.4	75
233	Minimal residual disease in multiple myeloma 2019. Advances in Cell and Gene Therapy, 2020, 3, e71.	0.9	1
234	An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma. International Journal of Laboratory Hematology, 2020, 42, e65-e67.	1.3	2
235	Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease. Cytometry Part B - Clinical Cytometry, 2020, 98, 161-173.	1.5	20
236	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. Journal of Clinical Oncology, 2020, 38, 784-792.	1.6	175
237	Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. Cancers, 2020, 12, 15.	3.7	39
238	CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab. Cytometry Part B - Clinical Cytometry, 2021, 100, 497-508.	1.5	22

#	Article	IF	Citations
239	An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma. Expert Review of Hematology, 2020, 13, 795-802.	2.2	4
240	Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 724-735.	0.4	5
241	Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report. Medicine (United States), 2020, 99, e20726.	1.0	0
242	The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. PLoS ONE, 2020, 15, e0237155.	2.5	21
243	Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice. Journal of Personalized Medicine, 2020, 10, 120.	2.5	13
244	A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Advances, 2020, 4, 5988-5999.	5.2	198
245	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood, 2020, 136, 936-945.	1.4	436
246	Targeting Wnt Signaling for the Treatment of Gastric Cancer. International Journal of Molecular Sciences, 2020, 21, 3927.	4.1	46
247	Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. Frontiers in Oncology, 2020, 10, 860.	2.8	35
248	Measurable disease evaluation in patients with myeloma. Best Practice and Research in Clinical Haematology, 2020, 33, 101154.	1.7	2
249	CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma. Clinical Immunology, 2020, 213, 108363.	3.2	8
250	Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer, 2020, 20, 612.	2.6	72
251	Advanced imaging in evaluation of bone disease of multiple myeloma. Chinese Journal of Academic Radiology, 2020, 3, 76-83.	0.6	2
252	Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e769-e776.	0.4	2
253	Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan. International Journal of Hematology, 2020, 111, 519-529.	1.6	8
254	Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma. Frontiers in Oncology, 2020, 10, 1.	2.8	156
255	Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e221-e238.	0.4	9
256	Second malignancies in multiple myeloma; emerging patterns and future directions. Best Practice and Research in Clinical Haematology, 2020, 33, 101144.	1.7	27

#	Article	IF	Citations
257	Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. Bone Marrow Transplantation, 2020, 55, 1137-1146.	2.4	7
258	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. American Journal of Hematology, 2020, 95, 497-502.	4.1	35
259	Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. Blood Reviews, 2021, 46, 100732.	5.7	18
260	Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents. International Journal of Hematology, 2021, 113, 207-213.	1.6	9
261	Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye. Leukemia and Lymphoma, 2021, 62, 1544-1553.	1.3	4
262	Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer Journal, 2021, 11, 24.	6.2	77
263	Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial. British Journal of Haematology, 2021, 193, e19-e22.	2.5	3
264	MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. BMJ Open, 2021, 11, e046225.	1.9	18
265	Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood, 2021, 138, 113-121.	1.4	22
266	Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. Pathology, 2021, 53, 385-399.	0.6	12
267	Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive). Haematologica, 2021, 106, 2694-2706.	3.5	6
268	Minimal Residual Disease in Multiple Myeloma. Cancer Journal (Sudbury, Mass), 2021, 27, 247-255.	2.0	7
269	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplantation, 2021, 56, 2533-2543.	2.4	7
270	Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis. Journal of Cancer Research and Clinical Oncology, 2022, 148, 913-919.	2.5	5
271	Immune Gene Rearrangements: Unique Signatures for Tracing Physiological Lymphocytes and Leukemic Cells. Genes, 2021, 12, 979.	2.4	10
272	Flow cytometric myeloma measurable residual disease testing in the era of targeted therapies. International Journal of Laboratory Hematology, 2021, 43, 71-77.	1.3	0
273	Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders. Leukemia, 2021, 35, 2771-2783.	7.2	17
274	Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis. International Journal of Molecular Sciences, 2021, 22, 7470.	4.1	15

#	Article	IF	Citations
275	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood, 2022, 139, 492-501.	1.4	64
276	Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria. Scientific Reports, 2021, 11, 14956.	3.3	2
277	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood, 2022, 139, 835-844.	1.4	43
278	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research, 2021, 27, 5195-5212.	7.0	26
279	Minimal Residual Disease in Multiple Myeloma: Something Old, Something New. Cancers, 2021, 13, 4332.	3.7	6
280	Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry. Annals of Hematology, 2021, 100, 2989-2995.	1.8	3
281	Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. Cancers, 2021, 13, 4582.	3.7	28
282	Current concepts and future directions for hemato-oncologic diagnostics. Critical Reviews in Oncology/Hematology, 2020, 151, 102977.	4.4	14
283	Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematology American Society of Hematology Education Program, 2013, 2013, 496-503.	2.5	6
284	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. Hematology American Society of Hematology Education Program, 2014, 2014, 255-261.	2.5	16
285	Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?. Hematology American Society of Hematology Education Program, 2019, 2019, 142-147.	2.5	4
286	Myeloma in Elderly Patients: When Less Is More and More Is More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 575-585.	3.8	20
287	Thalidomide-induced serious RR interval prolongation (longest interval >5.0â€‰s) in multiple myeloma patient with rectal cancer: A case report. Open Medicine (Poland), 2020, 15, 540-544.	1.3	1
288	Minimal residual disease in plasma cell (multiple) myeloma: flow cytometric approaches. Oncogematologiya, 2020, 15, 40-50.	0.3	4
289	Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget, 2017, 8, 5924-5935.	1.8	33
290	Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. Korean Journal of Internal Medicine, 2016, 31, 809-819.	1.7	8
291	The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patientsple Myeloma Patients. Turkish Journal of Haematology, 2017, 34, 226-232.	0.5	12
292	Minimal residual disease monitoring: the new standard for treatment evaluation of haematological malignancies?. Swiss Medical Weekly, 2014, 144, w13907.	1.6	14

#	Article	IF	Citations
293	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1685-1717.	4.9	138
294	Minimal residual disease in multiple myeloma: current status. Biomarker Research, 2021, 9, 75.	6.8	12
295	A FZD7-specific Antibodyâ€"Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models. Molecular Cancer Therapeutics, 2022, 21, 113-124.	4.1	18
296	DETECTION OF MINIMAL TUMOR CELLS FOR THE DIAGNOSIS AND TREATMENT MONITORING OF CHILDREN WITH NEUROBLASTOMA. , 2021, 20, 10-16.	0.3	0
297	Taking the road less traveled â€" the therapeutic potential of CBP/Î²-catenin antagonists. Expert Opinion on Therapeutic Targets, 2021, 25, 701-719.	3.4	6
298	Treatment of elderly patients with myeloma. , 2015, , 41-63.		0
299	Role of Flow Cytometry in Plasma Cell Neoplasms. , 2016, , 101-122.		1
300	Flow Cytometric Analysis in the Diagnosis and Prognostication of Plasma Cell Neoplasms. , 2016, , 99-108.		0
301	Plasma Cell Disorders. , 0, , 235-250.		1
302	Risk Stratification in Newly Diagnosed Transplant-Eligible Multiple Myeloma. , 2018, , 15-36.		0
303	Risk Stratification in Newly Diagnosed Transplant Ineligible Multiple Myeloma. , 2018, , 37-58.		0
304	In Search of Missed Tumors: Next-Generation Sequencing for Minimal Residual Disease Detection in Multiple Myeloma Comes of Age. , 2019, 16, .		0
305	Minimal Residual Disease Assessment in Myeloma. , 2019, , 231-245.		0
306	Bone marrow MRI after autologous transplantation and the effect of residual tumor on progression-free survival of multiple myeloma patients. Oncogematologiya, 2019, 13, 46-53.	0.3	1
307	Myelomatous ascites: Flow cytometric diagnosis and evolution of phenotype. Indian Journal of Pathology and Microbiology, 2020, 63, 154.	0.2	0
308	Detection of Minimal Residual Disease. , 2020, , 701-711.		0
309	What is the role of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in the scenario of new drugs for Multiple Myeloma (MM). Journal of Bone Marrow Transplantation and Cellular Therapy, 2020, 1, 27-29.	0.1	0
316	Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time. Clinical Advances in Hematology and Oncology, 2019, 17, 559-568.	0.3	8

#	Article	IF	Citations
317	Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: A retrospective analysis. Leukemia Research, 2022, 112, 106750.	0.8	1
318	Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia. Seminars in Oncology, 2021, , .	2.2	0
319	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Advances, 2022, 6, 808-817.	5.2	14
320	Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data. Journal of Cancer Research and Therapeutics, 2021, 17, 1515.	0.9	2
321	Evaluation of cytokine profile in the different phases of the autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Transplant Immunology, 2022, 70, 101513.	1.2	0
322	Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis. Hematology, 2021, 26, 1031-1039.	1.5	3
323	Pretransplant Determinants of Outcome in Patients with Myeloma Undergoing Autologous Transplantation in Lower Resource Settings. European Medical Journal (Chelmsford, England), 0, , 101-110.	3.0	0
324	Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications. Frontiers in Oncology, 2021, 11, 801851.	2.8	13
325	Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis. Cytometry Part B - Clinical Cytometry, 2022, 102, 88-106.	1.5	10
326	The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes. Expert Review of Clinical Pharmacology, 2022, , 1-13.	3.1	2
327	Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission â€“ results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. BMC Cancer, 2022, 22, 147.	2.6	1
328	The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S.. Seminars in Oncology, 2022, 49, 3-10.	2.2	3
330	Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome. British Journal of Haematology, 2022, , .	2.5	1
331	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology, 2022, 40, 2889-2900.	1.6	29
332	Effectiveness and safety of chemotherapy combined with immunomodulatory therapies for multiple myeloma. Medicine (United States), 2022, 101, e29093.	1.0	0
334	Evolution or revolution in multiple myeloma therapy and the role of the UK. British Journal of Haematology, 2020, 191, 542-551.	2.5	3
339	A novel Î²-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer. Science Advances, 2022, 8, eabm3108.	10.3	10
340	MRD in multiple myeloma: does CR really matter?. Blood, 2022, 140, 2423-2428.	1.4	12

#	Article	IF	Citations
341	Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT. Frontiers in Oncology, 2022, 12, .	2.8	2
342	Effect of the sequence of pull of bone marrow aspirates on plasma cell quantification in plasma cell proliferative disorders. International Journal of Laboratory Hematology, 2022, 44, 837-845.	1.3	4
343	Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?. Hemato, 2022, 3, 385-413.	0.6	2
344	Impact of autologous hematopoietic cell transplantation on disease burden quantified by nextâ€generation sequencing in multiple myeloma treated with quadruplet therapy. American Journal of Hematology, 2022, 97, 1170-1177.	4.1	3
345	Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy. Transplantation and Cellular Therapy, 2022, 28, 760.e1-760.e5.	1.2	3
346	Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy. Frontiers in Oncology, 0, 12, .	2.8	5
347	Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside. Experimental Hematology and Oncology, 2022, 11, .	5.0	3
348	Upfront Autologous Stem Cell Transplantation (ASCT) vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation with K Maintenance in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Phase 2 Non-Inferiority Cardamon Study. SSRN Electronic Journal, 0, . .	0.4	0
349	Multiple Myeloma: Nuances of Minimal Residual Disease Diagnosis and Monitoring with the Use of Multicolor Flow Cytometry. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2022, 15, 365-376.	0.4	0
350	Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and Perspective. Clinical Hematology International, 2022, 4, 127-132.	1.7	2
351	Steps towards a Multiple Myeloma Cure?. Journal of Personalized Medicine, 2022, 12, 1451.	2.5	3
353	CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy. Frontiers in Immunology, 0, 13, .	4.8	4
354	Effectiveness of D-Rd program in the first line therapy of a 75-year-old female patient with multiple myeloma with high-risk cytogenetics. Clinical observation. , 2022, 2, 28-35.		1
355	Graded Depth of Response and Neoplastic Plasma Cell Index as Indicators of Survival Outcomes in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant. American Journal of Clinical Pathology, 2023, 159, 69-80.	0.7	1
356	Risk and response adapted therapy following autologous stem cell transplant in patients with newly		

#	Article	IF	Citations
360	Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry. Indian Journal of Medical and Paediatric Oncology, 0, , .	0.2	0
361	Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment. Cancers, 2023, 15, 2418.	3.7	0
362	Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. Journal of Clinical Oncology, 2023, 41, 3945-3955.	1.6	12
363	Response adaptive salvage with <scp>KTd</scp> and <scp>ASCT</scp> for functional highâ€risk multiple myelomaâ€"The Australasian Leukemia and Lymphoma Group (<scp>ALLG</scp>) <scp>MM17</scp> Trial. British Journal of Haematology, 2023, 202, 530-538.	2.5	1
364	Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting. Biomedicines, 2023, 11, 2087.	3.2	1
365	Discriminating minimal residual disease status in multiple myeloma based on MRI: utility of radiomics and comparison of machine-learning methods. Clinical Radiology, 2023, , .	1.1	0
366	Multiples Myelom. , 2023, , 65-69.		0
367	Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future. Cancers, 2023, 15, 3687.	3.7	1
368	Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients. Haematologica, 2024, 109, 974-978.	3.5	0
369	Safety and efficacy of a new highâ€dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage <scp>ASCT</scp> for refractory/relapsed or highâ€risk myeloma: Matchedâ€pair comparisons with concurrent control cohorts. American Journal of Hematology, 0, , .	4.1	0
370	Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial. Bone Marrow Transplantation, 2024, 59, 431-434.	2.4	0
372	Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma. Discover Oncology, 2024, 15, .	2.1	0